Group 1 - The core viewpoint of the articles highlights the performance and valuation of Chongqing Shanwaishan Blood Purification Technology Co., Ltd., particularly its stock price, market capitalization, and industry comparisons [1][2]. - As of August 8, the company's stock closed at 16.56 yuan, reflecting a 2.79% increase, with a rolling PE ratio of 72.24, marking a new low in 11 days, and a total market capitalization of 5.321 billion yuan [1]. - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, positioning Shanwaishan at the 93rd rank within the industry [1][3]. Group 2 - Chongqing Shanwaishan specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2]. - The company's main products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2]. - In the latest quarterly report for Q1 2025, the company reported revenue of 189 million yuan, a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, reflecting a year-on-year growth of 8.10%, with a gross profit margin of 46.72% [2].

Core Viewpoint - The report details the equity changes of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. due to the share reduction by major shareholders, which does not trigger a change in control or a mandatory tender offer [19][20][22]. Group 1: Shareholder Information - The equity change involves three main parties: Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Dajiankang Venture Capital Partnership (Limited Partnership), Hunan Xiangjiang Liyuan Investment Management Co., Ltd. - Hunan Xiangjiang Liyuan Jiankun Venture Capital Partnership (Limited Partnership), and the original shareholder You Xinnong [19][20]. - The total shares held by these parties decreased from 18,623,449 shares (12.87% of total shares) to 32,131,623 shares (10.00% of total shares) after the reduction [22]. Group 2: Share Reduction Details - The share reduction was executed through centralized bidding transactions, with You Xinnong reducing 1,937,703 shares from June 18, 2024, to September 15, 2024, and the other two parties reducing a total of 7,276,593 shares from June 6, 2025, to August 4, 2025 [8][20][22]. - The total share capital of the company increased from 144,730,259 shares at the time of listing to 321,315,646 shares after two rounds of capital reserve transfers [7][22]. Group 3: Future Plans - The parties involved have no current plans to increase or decrease their holdings beyond the disclosed reduction plan, which allows for a maximum reduction of 12,852,625 shares, representing up to 4.00% of the total share capital [5][20]. - The report confirms that the equity change does not affect the company's controlling shareholder or actual controller [9][19].

证券代码：688410 证券简称：山外山 公告编号：2025-035 重庆山外山血液净化技术股份公司 关于持股 5%以上股东权益变动触及 5%整数倍的 提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 重要内容提示： ? 本次权益变动为重庆山外山血液净化技术股份有限公司（以下简称"公 司"或"山外山"）股东湖南湘江力远投资管理有限公司－湖南湘江大健康创业 投资合伙企业（有限合伙）（以下简称"大健康"或"信息义务披露人一"）、 湖南湘江力远投资管理有限公司－湖南湘江力远健鲲创业投资合伙企业（有限合 伙）（以下简称"力远健鲲"或"信息义务披露人二"）及原股东游新农（以下 简称"信息义务披露人三"）履行此前披露的减持股份计划，通过集中竞价交易 方式减持所致，不触及要约收购。 ? 本次权益变动为持股5%以上非第一大股东减持，不会使公司控股股东、 实际控制人发生变化。 注册地址 湖南省长沙市高新开发区麓谷大道 627 号长海创业基地三楼 执行事务合伙人 湖南湘江力远投资管理有限公司 以自有资产进行股权投资；投资 ...

据统计，8月4日，盘后包括达意隆、山外山、开普检测、吉宏股份、红旗连锁、通达股份、神火股份、 康泰医学、步科股份、飞鹿股份、能辉科技、晶雪节能、胜宏科技、赛腾股份、雪迪龙、中芯国际、工 大高科、成都先导、飞乐音响、华电辽能、三维股份、奥锐特在内的22家A股上市公司披露减持情况。 当日暂无A股上市公司披露增持情况。 | 1 | 达意障 | 董事兼高级管理人员吴小满计划减持不超过4.22万股股份 | | --- | --- | --- | | 2 | 山外山 | 大健康和力远健鲲合计减持2.26%公司股份 | | 3 | 开普检测 | 副总经理贺春、张冉拟减持不超过0.54%公司股份 | | 4 | 吉宏股份 | 毒事长干亚朋计划减持不超过304万股 | | 5 | 红旗连锁 | 永辉超市拟减持不超过1%股份 | | 6 | 通达股份 | 控股股东拟减持不超过3%公司股份 | | 1 | 神火股份 | 普天工贸拟减持0.90%公司股份 | | 8 | 康泰医学 | 持股5%以上股东及部分董事、高管拟减持不超过3.59%股份 | | 9 | 步科股份 | 控股股东上海步进计划减持不超过3%公司股份 | | 10 | ...

格隆汇8月4日丨山外山(688410.SH)公布，2025年6月6日至2025年8月4日，大健康和力远健鲲通过集中 竞价交易方式合计减持公司727.66万股，占公司总股本的2.26%。 ...

本次权益变动为持股5%以上非第一大股东减持，不会使公司控股股东、 实际控制人发生变化。 重要内容提示： 本次权益变动为重庆山外山血液净化技术股份有限公司（以下简称"公 司"或"山外山"）股东湖南湘江力远投资管理有限公司－湖南湘江大健康创业 投资合伙企业（有限合伙）（以下简称"大健康"或"信息义务披露人一"）、 湖南湘江力远投资管理有限公司－湖南湘江力远健鲲创业投资合伙企业（有限合 伙）（以下简称"力远健鲲"或"信息义务披露人二"）及原股东游新农（以下 简称"信息义务披露人三"）履行此前披露的减持股份计划，通过集中竞价交易 方式减持所致，不触及要约收购。 本次权益变动后，信息披露义务人合计持有公司股份数量为32,131,623 股，占公司总股本的10.00%。 公司于2025年8月4日收到信息披露义务人出具的《简式权益变动报告书》， 自2024年6月18日至2025年8月4日，信息披露义务人通过集中竞价交易方式减持 公司股份，导致合计持股比例由12.87%减少至10.00%，根据中国证券监督管理委 员会《上市公司收购管理办法》《证券期货法律适用意见第19号——<上市公司 收购管理办法>第十三条、第十四条的适用意 ...

重庆山外山血液净化技术股份有限公司 简式权益变动报告书 上市公司名称：重庆山外山血液净化技术股份有限公司 信息披露义务人一：湖南湘江力远投资管理有限公司－湖南湘江大健康创 业投资合伙企业（有限合伙） 住所：湖南省长沙市高新开发区麓谷大道627号长海创业基地三楼 股份变动性质：减持股份 住所：湖南省长沙市****** 股份变动性质：减持股份 签署日期：2025年 8 月 4 日 股票简称：山外山 股票代码：688410 股票上市地点：上海证券交易所 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称《证券法》） 、《上市公司收购管理办法》（以下简称《收购管理办法》）、《公开发行证券 的公司信息披露内容与格式准则第 15 号-权益变动报告书》（以下简称《准则 15 号》）及其他相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 信息披露义务人二：湖南湘江力远投资管理有限公司－湖南湘江力远健鲲创 业投资合伙企业（有限合伙） 住所：湖南省长沙市高新开发区岳麓西大道588 ...

Group 1 - The core viewpoint of the news is that Chongqing Shanwaishan Blood Purification Technology Co., Ltd. has shown a significant increase in stock price and market capitalization, with a current PE ratio of 69.53, which is higher than the industry average of 54.32 [1][3] - As of March 31, 2025, the number of shareholders for the company has increased to 7,938, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, and sales of blood purification equipment and consumables, and has received multiple national awards for its innovations in the field [2] Group 2 - In the latest quarterly report for Q1 2025, the company reported a revenue of 189 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 37.06 million yuan, with a year-on-year growth of 8.10% [2] - The company's gross profit margin stands at 46.72%, indicating a strong profitability in its operations [2] - The company ranks 92nd in the medical device industry based on PE ratio, which reflects its relative valuation compared to peers [1][3]

Stock Recommendations - Jerry Holdings (002353.SZ) shows strong overseas growth potential with a steady increase in orders and confidence from management through share buybacks[4] - Guoneng Rixin (301162.SZ) reported a 40.14% year-on-year revenue growth in Q1 2025, with a net profit growth of 104.81%[25] - Ruihu Mould (002997.SZ) achieved a revenue of 1.662 billion yuan, up 48.3% year-on-year, and a net profit of 227 million yuan, up 40.33%[26] - Shanhua Mountain (688410.SH) benefits from the recovery of blood dialysis machine tenders, leading to increased sales[27] - Yuanjie Technology (688498.SH) has a diverse product matrix with significant orders, indicating potential for improved profitability[28] - Gigabit (603444.SH) launched successful new games, with the mobile game "Zhang Jian Chuan Shuo" achieving top rankings, suggesting a positive outlook for 2025[29] - Shangmei Co., Ltd. (2145.HK) reported impressive sales during the 618 shopping festival, indicating strong brand performance and growth potential[30] Market Performance - The weighted return of the stock portfolio in July was -0.22%, while the equal-weighted return was 8.68%[14] - The Shanghai Composite Index rose by 4.97% in July, with the ChiNext Index increasing by 9.97%[14] - The best-performing stocks in July included Haopeng Technology with a return of 41.54% and Daotong Technology with 17.61%[15] Risk Factors - Economic recovery and policy support may fall short of expectations, posing risks to the market[31] - Individual company operational risks could impact stock performance[31]

Company Overview - Chongqing Shanwaishan Blood Purification Technology Co., Ltd. specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2] - The main products include blood perfusion machines, continuous blood purification devices, blood dialysis machines, and various blood purification consumables [2] - The company has received multiple national and provincial awards for its technological innovations, including the National Science and Technology Progress Award [2] Financial Performance - For Q1 2025, the company reported a revenue of 189 million yuan, representing a year-on-year increase of 16.77% [2] - The net profit for the same period was approximately 37.01 million yuan, reflecting a year-on-year growth of 8.10% [2] - The sales gross margin stood at 46.72% [2] Market Position - As of July 31, the company's stock closed at 15.86 yuan, down 2.10%, with a rolling price-to-earnings (PE) ratio of 69.18 times [1] - The average PE ratio for the medical device industry is 54.89 times, with a median of 37.06 times, placing the company at the 92nd position in the industry ranking [1][3] - The total market capitalization of the company is approximately 5.096 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders reached 7,938, an increase of 979 from the previous count [1] - The average market value of shares held by each shareholder is approximately 352,800 yuan, with an average holding of 27,600 shares [1]